Abstract
The idea that within the bulk of leukemic cells there are immature progenitors which are intrinsically resistant to chemotherapy and able to repopulate the tumor after treatment is not recent. Nevertheless, the term leukemia stem cells (LSCs) has been adopted recently to describe these immature progenitors based on the fact that they share the most relevant features of the normal hematopoetic stem cells (HSCs), i.e. the self-renewal potential and quiescent status. LSCs differ from their normal counterparts and from the more differentiated leukemic cells regarding the default status of pathways regulating apoptosis, cell cycle, telomere maintenance and transport pumps activity. In addition, unique features regarding the interaction of these cells with the microenvironment have been characterized. Therapeutic strategies targeting these unique features are at different stages of development but the reported results are promising. The aim of this review is, by taking acute myeloid leukemia (AML) as a bona fide example, to discuss some of the mechanisms used by the LSCs to survive and the strategies which could be used to eradicate these cells.
Keywords: Leukemia stem cells, acute myeloid leukemia, bone marrow microenvironment
Anti-Cancer Agents in Medicinal Chemistry
Title: Targeting the Acute Myeloid Leukemia Stem Cells
Volume: 10 Issue: 2
Author(s): Alexandre Krause, Luciana M. Fontanari Krause and Eduardo M. Rego
Affiliation:
Keywords: Leukemia stem cells, acute myeloid leukemia, bone marrow microenvironment
Abstract: The idea that within the bulk of leukemic cells there are immature progenitors which are intrinsically resistant to chemotherapy and able to repopulate the tumor after treatment is not recent. Nevertheless, the term leukemia stem cells (LSCs) has been adopted recently to describe these immature progenitors based on the fact that they share the most relevant features of the normal hematopoetic stem cells (HSCs), i.e. the self-renewal potential and quiescent status. LSCs differ from their normal counterparts and from the more differentiated leukemic cells regarding the default status of pathways regulating apoptosis, cell cycle, telomere maintenance and transport pumps activity. In addition, unique features regarding the interaction of these cells with the microenvironment have been characterized. Therapeutic strategies targeting these unique features are at different stages of development but the reported results are promising. The aim of this review is, by taking acute myeloid leukemia (AML) as a bona fide example, to discuss some of the mechanisms used by the LSCs to survive and the strategies which could be used to eradicate these cells.
Export Options
About this article
Cite this article as:
Krause Alexandre, Fontanari Krause M. Luciana and Rego M. Eduardo, Targeting the Acute Myeloid Leukemia Stem Cells, Anti-Cancer Agents in Medicinal Chemistry 2010; 10 (2) . https://dx.doi.org/10.2174/187152010790909281
DOI https://dx.doi.org/10.2174/187152010790909281 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Disulfide Analogues of Isophosphoramide Mustard for Anticancer Therapy
Letters in Drug Design & Discovery Recent Advances in the Development of Dual Topoisomerase I and II Inhibitors as Anticancer Drugs
Current Medicinal Chemistry Biological Basis of Novel Therapies for Myelodysplastic Syndrome
Current Cancer Therapy Reviews Regulatory Circuitries Coordinated by Transcription Factors and microRNAs at the Cornerstone of Hematopoietic Stem Cell Self-Renewal and Differentiation
Current Stem Cell Research & Therapy HSP90 Inhibitors: Current Development and Potential in Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery The Protein Profile of Fibroblasts: The Role of Proteomics
Current Proteomics Molecular Targeting of Protein Kinases to Optimize Selectivity and Resistance Profiles of Kinase Inhibitors
Current Topics in Medicinal Chemistry Harnessing the Tumor Suppressor Function of FOXO as an Alternative Therapeutic Approach in Cancer
Current Drug Targets Trends in Cell-Based Electrochemical Biosensors
Current Medicinal Chemistry Targeted Therapy for Advanced Renal Cell Cancer: Cytokines and Beyond
Current Pharmaceutical Design Lycopene: A Review of Its Potential as an Anticancer Agent
Current Medicinal Chemistry - Anti-Cancer Agents Management of Early Stage Chronic Myeloid Leukemia: State-of-the-art Approach and Future Perspectives
Current Cancer Drug Targets Royal Jelly Acid, 10-Hydroxy-trans-2-Decenoic Acid, as a Modulator of the Innate Immune Responses
Endocrine, Metabolic & Immune Disorders - Drug Targets Inhibition of Apoptosis in Pediatric Cancer by Survivin
Current Pediatric Reviews Distinctive Cellular Roles for Novel Protein Kinase C Isoenzymes
Current Pharmaceutical Design H3K4 Methylation Status and Lysine Specific Methyltransferase KMT2C Expression Correlate with Prognosis in Lung Adenocarcinoma
Current Molecular Pharmacology Targeted Therapy Towards Cancer-A Perspective
Anti-Cancer Agents in Medicinal Chemistry Antioxidant Supplements, Genetics and Chemotherapy Outcomes
Current Cancer Therapy Reviews Huntingtons Disease: New Frontiers for Molecular and Cell Therapy
Current Drug Targets The PA207 Peptide Inhibitor of LIM-only Protein 2 (Lmo2) Targets Zinc Finger Domains in a Non-specific Manner
Protein & Peptide Letters